Subscribe To
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
oncolytics biotech inc. (oncy) q3 2023 earnings call transcript
oncolytics Biotech Inc. (NASDAQ:ONCY ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Com...
November 3, 2023, 9:05 pm
After plunging -29.54% in 4 weeks, here's why the trend might reverse for oncolytics biotech inc. (oncy)
The heavy selling pressure might have exhausted for oncolytics Biotech Inc. (ONCY) as it is technically...
August 17, 2023, 11:02 am
oncolytics biotech inc. (oncy) q2 2023 earnings call transcript
oncolytics Biotech Inc. (NASDAQ:ONCY ) Q2 2023 Earnings Conference Call August 14, 2023 8:30 AM ET Comp...
August 14, 2023, 11:48 am
Replimune: the rise of oncolytic virus therapies in cancer treatment
The company's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Top-line results from ...
July 9, 2023, 1:22 am
oncolytics: proof of concept in 2 large market indications
Positive results achieved, in using pelareorep + paclitaxel for the treatment of HR+/HER2- metastatic breast cancer patients, in the phase 2 BRACELET-...
July 3, 2023, 5:39 pm
Theriva biologics jumps on us fda approval for pancreatic cancer treatment
Theriva Biologics Inc saw its shares surge over 70% higher in after-hours US trading following news that its lead clinical candidate, VCN-01, has bee...
June 28, 2023, 8:51 am
Calidi biotherapeutics announces commitment of $25 million in series b funding to advance stem cell-based platforms for the delivery and potentiation of oncolytic viruses to treat cancer
Financing led by Jackson Investment Group (JIG) with participation from Calidi Cure, LLC, a consortium of new and existing investors led by Allan Cama...
June 23, 2023, 9:00 am
oncolytics biotech's stock soars 25% after pelareorep is selected for inclusion in late-stage pancreatic cancer trial
The stock of oncolytics Biotech Inc. ONCY, +23.25% soared 25% Thursday, after the San Diego-based compa...
June 22, 2023, 1:12 pm
oncolytics biotech® to participate in a panel presentation at canaccord genuity's horizons in oncology virtual conference
SAN DIEGO and CALGARY, AB , April 12, 2023 /PRNewswire/ -- oncolytics Biotech® Inc. (NASDAQ: ONCY) (T...
April 12, 2023, 7:23 am
Genelux: recent ipo with phase 3 stage oncolytic virus cancer therapy
GNLX IPO-ed recently, but the company has been around for two decades. The company develops an oncolytic...
March 26, 2023, 10:50 pm
oncolytics biotech inc. (oncy) q4 2022 earnings call transcript
oncolytics Biotech Inc. (NASDAQ:ONCY ) Q4 2022 Earnings Conference Call March 3, 2023 8:30 AM ET Compan...
March 3, 2023, 11:40 am
Is dice therapeutics (dice) stock outpacing its medical peers this year?
Here is how DICE Therapeutics, Inc. (DICE) and oncolytics Biotech Inc. (ONCY) have performed compared t...
December 16, 2022, 11:18 am
Replimune announces pricing of public offering
BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of ...
December 9, 2022, 2:04 am
What makes oncolytics biotech inc. (oncy) a strong momentum stock: buy now?
Does oncolytics Biotech Inc. (ONCY) have what it takes to be a top stock pick for momentum investors? L...
December 5, 2022, 1:33 pm
oncolytics (oncy) up on lead drug securing 2nd fda fast track tag
oncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with R...
December 2, 2022, 12:02 pm
Imugene’s oncarlytics combination with celularity’s placental-derived off-the-shelf allogeneic cycart-19 t cells preclinical data presented at sitc annual meeting
SYDNEY, Australia and FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) — Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company and C...
November 10, 2022, 10:00 pm